Skip to main content

Advances in the pathology of gynecologic cancer

  • Chapter
Gynecologic Oncology

Part of the book series: Cancer Treatment and Research ((CTAR,volume 95))

  • 93 Accesses

Abstract

Pathology is often seen as a relatively static branch of medicine, with pathologists relying on the classical techniques of diagnostic light microscopy working in the sheltered environment of a laboratory that is far removed from clinical decision making. The real image of the contempory pathologist differs markedly, however, from this conventional, and outdated, view of a ‘backroom worker’ rooted in a scientific time warp. It is true that straightforward light microscopic diagnosis remains as the bedrock of gynecological pathology, but pathologists are now concerned as much with defining tumor-associated prognostic factors as they are with specific diagnosis and are, or should be, members of the oncological team that determines the management of patients with malignant disease of the female genital tract.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 429.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 549.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 549.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Nogales FF (1995) Mesonephric (Wolffian) tumours of the female genital tract: Is meso-nephric histogenesis a mirage and a trap?. Curr Diag Pathol 2:94–100.

    Article  Google Scholar 

  2. Ishikura H, Scully RE (1987) Hepatoid carcinoma of the ovary. Cancer 60:2775–2784.

    Article  PubMed  CAS  Google Scholar 

  3. Young RH, Eichhorn JH, Dickersin GR, Scully RE (1992) Ovarian involvement by the intraabdominal desmoplastic small round cell tumor with divergent differentiation: A report of three cases. Hum Pathol 23:454–464.

    Article  PubMed  CAS  Google Scholar 

  4. Zaloudek C, Miller TR, Stern JL (1995) Desmoplastic small cell tumor of the ovary: A unique polyphenotypic tumor with an unfavourable prognosis. Int J Gynecol Pathol 14:260–265.

    Article  PubMed  CAS  Google Scholar 

  5. Eichhorn JH, Young RH, Scully RE (1992) Primary ovarian small cell carcinoma of pulmonary type: A clinicopathologic, immunohistologic and flow cytometric analysis of 11 cases. Am J Surg Pathol 19:926–938.

    Article  Google Scholar 

  6. Gersell DJ, Mazoujian G (1988) Small cell undifferentiated carcinoma of the cervix. Am J Surg Pathol 12:684–698.

    Article  PubMed  CAS  Google Scholar 

  7. Abeler VM, Holm R, Nesland JM, Kjorstadt KE (1994) Small cell carcinoma of the cervix. Cancer 73:672–677.

    Article  PubMed  CAS  Google Scholar 

  8. van Hoeven KH, Hudock JA, Woodruff JM, Suherland MJ (1995) Small cell neuroendocrine carcinoma of the endometrium. Int J Gynecol Pathol 14:21–29.

    Article  PubMed  Google Scholar 

  9. Ferry JA, Scully RE (1988) ‘Adenoid cystic’ carcinoma and adenoid basal carcinoma of the uterine cervix: A study of 28 cases. Am J Surg Pathol 12:134–144.

    Article  PubMed  CAS  Google Scholar 

  10. Rutgers JL, Scully RE (1988) Ovarian Mullerian mucinous papillary cystadenomas of borderline malignancy: A clinicopathologic analysis. Cancer 61:340–348.

    Article  PubMed  CAS  Google Scholar 

  11. Rahily MA, Williams ARW, Al-Nafussii A (1992) Minimal deviation endometrioid adenocarcinoma of cervix: A clinicopathological and immunohistochemical study of two cases. Histopathology 20:351–354.

    Article  Google Scholar 

  12. Young RH, Scully RE (1993) Minimal-deviation endometrioid adenocarcinoma of the uterine cervix: A report of five cases of a distinctive neoplasm that may be interpreted as benign. Am J Surg Pathol 17:660–665.

    Article  PubMed  CAS  Google Scholar 

  13. Ferry JA, Young RH, Engel G, Scully RE (1994) Oxyphilic Sertoli cell tumor of the ovary: A report of three cases, two in patients with the Peutz-Jeghers syndrome. Int J Gynecol Pathol 13:259–266.

    Article  PubMed  CAS  Google Scholar 

  14. Young RH, Scully RE (1989) Villoglandular papillary adenocarcinoma of the uterine cervix: A clinicopathologic analysis of 13 cases. Cancer 63:1773–1779.

    Article  PubMed  CAS  Google Scholar 

  15. Jones MW, Silverberg SG, Kurman RJ (1993) Well-differentiated villoglandular adenocarcinoma of the uterine cervix: A clinicopathological study of 24 cases. Int J Gynecol Pathol 12:1–7.

    Article  PubMed  CAS  Google Scholar 

  16. Fletcher CDM, Tsang WYW, Fisher C, Lee KC, Chan JKC (1992) Angiomyofibroblastoma of the vulva: A benign neoplasm distinct from aggressive angiomyxoma. Am J Surg Pathol 16:373–382.

    Article  PubMed  CAS  Google Scholar 

  17. Devaney K, Snyder R, Norris HJ, Tavassoli FA (1993) Proliferative and histologically malignant struma ovarii: A clinicopathologic study of 54 cases. Int J Gynecol Pathol 12:333–343.

    Article  PubMed  CAS  Google Scholar 

  18. Fox H, Harris M, McWilliam LJM, Wells M, Anderson GS (1988) Enteric tumours of the lower female genital tract: A report of three cases. Histopathology 12:167–176.

    Article  PubMed  CAS  Google Scholar 

  19. Benjamin E (1995) Immunohistochemical markers in gynaecological pathology. In: Fox H, ed. Obstetrical and Gynaecological Pathology, 4th ed. New York: Churchill Livingstone, pp. 1371–1392.

    Google Scholar 

  20. Young RH, Gilks CB, Scully RE (1991) Mucinous tumors of the appendix associated with mucinous tumors of the ovary and pseudomyxoma peritonei: A clinicopathologic analysis of 22 cases. Am J Surg Pathol 15:415–429.

    Article  PubMed  CAS  Google Scholar 

  21. Prayson RA, Hart WR, Petras RE (1994) Pseudomyxoma peritonei: A clinicopathologic study of 19 cases with emphasis on site of origin and nature of associated ovarian tumors. Am J Surg Pathol 19:591–603.

    Google Scholar 

  22. Ronnett BM, Kurman RJ, Zahn CM, et al. (1995) Pseudomyxoma peritonei in women: A clinicopathologic analysis of 30 cases with emphasis on site of origin, prognosis, and relationship to ovarian tumors of low malignant potential. Hum Pathol 26:509–524.

    Article  PubMed  CAS  Google Scholar 

  23. Fox H (1996) Ovarian tumours of borderline malignancy: Time for a reappraisal? Curr Diag Pathol 3, in press.

    Google Scholar 

  24. Kurman RJ, Trimble CL (1993) The behaviour of serous tumors of low malignant potential: Are they ever malignant?. Int J Gynecol Pathol 12:120–127.

    Article  PubMed  CAS  Google Scholar 

  25. Burks RT, Sherman RE, Kurman RJ (1996) Micropapillary serous carcinoma of the ovary and peritoneum: A distinctive low grade carcinoma related to serous borderline tumors. In press.

    Google Scholar 

  26. Seidman ME, Kurman RJ (1996) Subclassification of serous borderline tumors of the ovary into benign and malignant types: A clinicopathological study of 65 cases. In press.

    Google Scholar 

  27. Twiggs LB, Okagaki T, Clark B, Fukushima M, Ostrow R, Faras A (1988) A clinical, histopathologic, and molecular biologic investigation of vulvar intraepithelial neoplasia. Int J Gynecol Pathol 7:48–55.

    Article  PubMed  CAS  Google Scholar 

  28. Haefner H, Tate J, McLachin C, Crum C (1995) Vulvar intraepithelial neoplasia: Age, morphological phenotype, papillomavirus DNA, and coexisting invasive carcinoma. Hum Pathol 26:147–154.

    Article  PubMed  CAS  Google Scholar 

  29. Lininger RA, Tavassoli FA (1996) The pathology of vulvar neoplasia. Curr Opin Obstet Gynecol 8:63–68.

    Article  PubMed  CAS  Google Scholar 

  30. Chafe W, Richards A, Morgan L, Wilkinson EJ (1988) Unrecognized invasive carcinoma in vulvar intraepithelial neoplasia (VIN). Gynecol Oncol 31:154–165.

    Article  PubMed  CAS  Google Scholar 

  31. Jones R, Rowan D (1994) Vulvar intraepithelial neoplasia III: A clinical study of the outcome in 113 cases with relation to the later development of invasive vulvar carcinomaa. Obstet Gynecol 84:741–745.

    PubMed  CAS  Google Scholar 

  32. Toki T, Kurman RJ, Park JS, Kessis T, Daniel RW, Shah KV (1991) Probable nonpapillomavirus etiology of squamous cell carcinoma of the vulva in older women: A clinicopathologic study using in-situ hybridization and polymerase chain reaction. Int J Gynecol Pathol 10:107–125.

    Article  PubMed  CAS  Google Scholar 

  33. Kurman RJ, Toki T, Schiffman MH (1993) Basaloid and warty carcinomas of the vulva: Distinctive types of squamous cell carcinoma frequently associated with human papillomavirus. Am J Surg Pathol 17:133–145.

    Article  PubMed  CAS  Google Scholar 

  34. Monk B, Burger R, Lin F, Parham G, Vasilev S, Wilczynski S (1995) Prognostic significance of human papillomavirus DNA in vulvar carcinoma. Obstet Gynecol 85:709–715.

    Article  PubMed  CAS  Google Scholar 

  35. Foote AJ, Proietto A (1994) Stage 1 endometrial cancer: Treatment modalities and factors influencing recurrence. Aust N Z J Obstet Gynaecol 34:448–452.

    Article  PubMed  CAS  Google Scholar 

  36. Lampe B, Kurxl R, Hantschmann P (1994) Prognostic factors that predict pelvic lymph node metastasis from endometrial carcinoma. Cancer 74:2502–2508.

    Article  PubMed  CAS  Google Scholar 

  37. Nielsen AL, Thomsen HK, Nyholm HCJ (1991) Evaluation of the reproducibility of the revised 1988 Internationl Federation of Gynaecology and Obstetrics Grading System of endometrial cancers with special emphasis on nuclear grading. Cancer 68:2303–2309.

    Article  PubMed  CAS  Google Scholar 

  38. Zano RJ, Silverberg SG, Norris HJ, Bundy BN, Morrow CP, Okagagi K (1994) The prognostic value of nuclear versus architectural grading in endometrial carcinoma: A Gynecologic Oncology Group study. Int J Gynecol Pathol 13:29–36.

    Article  Google Scholar 

  39. Zano RJ, Kurman RJ, Diana KL, Morrow CP (1995) The utility of the revised International Federation of Gynecology and Obstetrics histologic grading of endometrial adenocarcinoma using a defined nuclear grading system: A Gynecologic Oncology Group study. Cancer 75:81–86.

    Article  Google Scholar 

  40. Perrone T, Dehner LP (1988) Prognostically favourable ‘mitotically active’ smooth muscle tumors of the uterus: A clinicopathologic study of ten cases. Am J Surg Pathol 12:1–8.

    Article  PubMed  CAS  Google Scholar 

  41. O’Connor DM, Norris HJ (1990) Mitotically active leiomyomas of the uterus. Hum Pathol 21:223–227.

    Article  PubMed  Google Scholar 

  42. Prayson RA, Hart WR (1992) Mitotically active leiomyomas of the uterus. Am J Clin Pathol 97:14–20.

    PubMed  CAS  Google Scholar 

  43. Chang KL, Crabtree GS, Lim-Tan SK, Kempson RL, Handrickson MR (1990) Primary uterine endometrial stromal neoplasms: A clinicopathologic study of 117 cases. Am J Surg Pathol 14:415–438.

    Article  PubMed  CAS  Google Scholar 

  44. van Dam PA, Watson JV, Lowe DG, Shepherd JH (1992) Flow cytometric DNA analysis in gynecological oncology. Int J Gynecol Cancer 2:57–65.

    Article  PubMed  Google Scholar 

  45. van Dam PA (1995) Ploidy in ovarian cancer and prognosis. In: Leake R, Gore M, Ward RH, eds. The Biology of Gynaecological Cancer. London: RCOG Press, pp. 258–273.

    Google Scholar 

  46. Kaern J, Iversen T, Trope C, Pettersen EO, Nesland JM (1992) Flow cytometric DNA measurements in squamous cell carcinoma of the vulva: An important prognostic method. Int J Gynecol Cancer 2:169–174.

    Article  PubMed  Google Scholar 

  47. Britton IC, Wilson TO, Gaffey TA, Cha SS, Wieand HS, Podratz KC (1990) DNA ploidy in endometrial carcinoma: Major objective prognostic factor. Mayo Clin Proc 65:643–650.

    PubMed  CAS  Google Scholar 

  48. Newbury R, Schuerch C, Godspeed N, Fanning J, Glidewell O, Evans M (1990) DNA content as a prognostic factor in endometrial carcinoma. Obstet Gynecol 76:251–257.

    PubMed  CAS  Google Scholar 

  49. Lindahl B, Gullberg B (1991) Flow cytometrical DNA and clinical parameters in the prediction of prognosis in Stage I–II endometrial cancer. Anticancer Res 11:397–401.

    PubMed  CAS  Google Scholar 

  50. Dyas CH, Simmons TK, Ellis CM, et al. (1992) Effect of desoxyribonucleic acid ploidy status on survival of patients with carcinoma of the endometrium. Surg Gynecol Obstet 174:133–136.

    PubMed  CAS  Google Scholar 

  51. Ikeda M, Watanabe Y, Nanjoh T, Noda K (1993) Evaluation of DNA ploidy in endometrial cancer. Gynecol Oncol 50:25–29.

    Article  PubMed  CAS  Google Scholar 

  52. Melchiorri C, Chieco P, Lisignoli G, Marabini A, Orlandi C (1993) Ploidy disturbance as an early indicator of intrinsic malignancy in endometrial carcinoma. Cancer 72:165–172.

    Article  PubMed  CAS  Google Scholar 

  53. Rodenberg CJ, Cornelisse CJ, Heintz PA, Hermans J, Fleuren GJ (1987) Tumor ploidy as a major prognostic factor in advanced ovarian cancer. Cancer 59:317–323.

    Article  Google Scholar 

  54. Volm M, Kleine W, Pfleiderer A (1989) Flow cytometric prognostic factors for the survival of patients with ovarian carcinoma: A 5 year follow-up study. Gynecol Oncol 35:84–89.

    Article  PubMed  CAS  Google Scholar 

  55. Klemi PJ, Joensuu H, Naenpaa J, Kiiholma P (1989) Influence of cellular DNA content on survival in ovarian carcinoma. Obstet Gynecol 74:200–204.

    PubMed  CAS  Google Scholar 

  56. Khoo SK, Hurst T, Kearsley GD, et al. (1990) Prognostic significance of tumor ploidy in patients with advanced ovarian cancer. Gynecol Oncol 39:284–288.

    Article  PubMed  CAS  Google Scholar 

  57. Jakobsen A, Bichel P, Stornes I (1991) Prognostic significance of DNA index in advanced ovarian cancer. Int J Gynecol Cancer 1:195–197.

    Article  Google Scholar 

  58. Vergote IB, Kaern J, Abeler VM, et al. (1993) Analysis of prognostic factors in stage I epithelial ovarian carcinoma: Importance of degree of differentiation and DNA ploidy in predicting relapse. Am J Obstet Gynecol 169:40–52.

    PubMed  CAS  Google Scholar 

  59. Gajewski WH, Fuller AF, Pastel-Ley C, et al. (1994) Prognostic significance of DNA content in epithelial ovarian cancer. Gynecol Oncol 53:5–12.

    Article  PubMed  CAS  Google Scholar 

  60. Kaern J, Trope CG, Kristensen CB, et al. (1994) Evaluation of DNA ploidy and S-phase fraction as prognostic parameters in advanced epithelial ovarian carcinoma. Am J Obstet Gynecol 170:479–487.

    PubMed  CAS  Google Scholar 

  61. Kigawa J, Minagawa Y, Ishihara H, Kanamori Y, Terakawa N (1993) Tumor DNA ploidy and prognosis of patients with serous cystadenocarcinoma of the ovary. Cancer 72:804–808.

    Article  PubMed  CAS  Google Scholar 

  62. Pfisterer J, Kommoss F, Sauerbrei A, et al. (1994) Cellular DNA content and survival in advanced ovarian cancer. Cancer 74:2509–2515.

    Article  PubMed  CAS  Google Scholar 

  63. Padberg P-C, Arps H, Franke U, et al. (1992) DNA cytophotometry and prognosis in ovarian tumors of borderline malignancy: A clinicopathological study of 80 cases. Cancer 69:2510–2514.

    Article  PubMed  CAS  Google Scholar 

  64. Kaern J, Trope CG, Kristensen GB, Abeler VM, Pettersen EO (1993) DNA ploidy: The most important prognostic factor in patients with borderline tumors of the ovary. Int J Gynecol Cancer 3:349–358.

    Article  PubMed  Google Scholar 

  65. Harlow BL, Fuhr JE, McDonald TW, Schwartz SM, Beuerlein FJ, Weiss NS (1993) Flow cytometry as a prognostic indicator in women with borderline epithelial ovarian tumors. Gynecol Oncol 50:305–309.

    Article  PubMed  CAS  Google Scholar 

  66. Kuoppala T, Heinola M, Aine R, Isola J, Heinonen PK (1996) Serous and mucinous borderline tumors of the ovary: A clinicopathologic and DNA-plody study of 102 cases. Int J Gynecol Cancer 6:302–308.

    Article  Google Scholar 

  67. Sykes P, Quinn M, Rome R (1997) Ovarian tumors of borderline malignancy: A retrospective study of 234 patients. Int J Gynecol Cancer 7:218–224.

    Article  Google Scholar 

  68. Klemi PJ, Joensuu H, Tuala S (1990) Prognostic value of flow cytometric DNA content analysis in granulosa cell tumors of the ovary. Cancer 65:1189–1193.

    Article  PubMed  CAS  Google Scholar 

  69. Holland DR, Le Riche J, Swenerton KD, Elit L (1991) Flow cytometric assessment of DNA ploidyis a useful prognostic factor for patients with granulosa cell ovarian tumors. Int J Gynecol Cancer 1:227–232.

    Article  Google Scholar 

  70. Hitchcock CL, Norris HJ, Khalifa MA, Wargotz ES (1989) Flow cytometric analysis of granulosa cell tumors. Cancer 64:2127–2132.

    Article  PubMed  CAS  Google Scholar 

  71. Swanson SA, Norris HJ, Kelsten ML, Wheeler JE (1990) DNA content of juvenile granulosa cell tumors determined by flow cytometry. Int J Gynecol Pathol 9:101–109.

    Article  PubMed  CAS  Google Scholar 

  72. Eichhorn JH, Young RH, Scully RE (1992) DNA content and proliferative activity in ovarian small cell carcinomas of the hypercalcemic type: Implications for diagnosis, prognosis and histogenesis. Am J Clin Pathol 98:579–586.

    PubMed  CAS  Google Scholar 

  73. Davis JR, Aristizabal S, Way DL, Weines SA, Hicks MJ, Hagaman RM (1989) DNA ploidy, grade, and stage in prognosis of uterine cervical cancer. Gynecol Oncol 32:4–7.

    Article  PubMed  CAS  Google Scholar 

  74. Kenter GG, Cornelisse CJ, Aartsen, et al. (1990) DNA ploidy level as prognostic factor in low stage carcinoma of the uterine cervix. Gynecol Oncol 39:181–185.

    Article  PubMed  CAS  Google Scholar 

  75. Ji HX, Syrjanen S, Klemi P, Chang F, Tosi P, Syrjanen K (1991) Prognostic significance of human papillomavirus (HPV) type and nuclear DNA content in invasive cervical cancer. Int J Gynecol Cancer 1:59–67.

    Article  Google Scholar 

  76. Strang P, Stendhal U, Bergstrom R, Frankendal B, Tribuait R (1991) Prognostic flow cytometric information in cervical squamous cell carcinoma: A multivariate analysis of 307 patients. Gynecol Oncol 43:3–8.

    Article  PubMed  CAS  Google Scholar 

  77. Zanetta GM, Katzmann JA, Keeney GL, Kinney WK, Cha SS, Podratz KC (1992) Flow-cytometric DNA analysis of stages IB and IIA cervical carcinoma. Gynecol Oncol 46:13–19.

    Article  PubMed  CAS  Google Scholar 

  78. Jarrell MA, Heintz N, Howard P, et al. (1992) Squamous cell carcinoma of the cervix: HPV 16 and DNA ploidy as predictors of survival. Gynecol Oncol 46:361–366.

    Article  PubMed  CAS  Google Scholar 

  79. Connor JP, Miller DS, Bauer KD, Murad TM, Rademaker AW, Lurain JR (1993) Flow cytometric evaluation of early invasive cervical cancer. Obstet Gynecol 81:367–371.

    PubMed  CAS  Google Scholar 

  80. Pfisterer J, Kommoss F, Sauerbrei W, et al. (1996) DNA flow cytometry in stage IB and II cervical carcinoma. Int J Gynecol Cancer 6:54–60.

    Article  Google Scholar 

  81. Putten HWHM, Baak JPA, Koenders TJM, et al. (1989) Prognostic value of quantitative pathologic features and DNA content in individual patients with stage I endometrial adenocarcinoma. Cancer 63:1378–1387.

    Article  PubMed  Google Scholar 

  82. Sorbe B, Risberg B, Thornthwaite J (1994) Nuclear morphometry and DNA flow cytometry as prognostic methods for endometrial carcinoma. Int J Gynecol Cancer 4:94–100.

    Article  PubMed  Google Scholar 

  83. Baak JPA, Langley FA, Talerman A, Delemarre JFM (1986) Morphometric data in the prognosis of ovarian tumours in addition to FIGO stage, histologic type and grade. J Clin Pathol 39:1340–1346.

    Article  PubMed  CAS  Google Scholar 

  84. Baak JPA, Wisse-Brekelmans ECM, Uyterlinde AM, Schipper NW (1987) Evaluation of the prognostic value of morphometric features and cellular DNA content in FIGO 1 ovarian cancer patients. Analyt Quant Cytol Histol 9:287–290.

    CAS  Google Scholar 

  85. Baak JPA, Schipper NW, Wisse-Brekelmans ECM, et al. (1988) The prognostic value of morphometrical features and cellular DNA content in cis-platin treated late ovarian cancer patients. Br J Cancer 57:503–508.

    Article  PubMed  CAS  Google Scholar 

  86. Haapasalo H, Collan Y, Atkin NB, Personen E, Seppa A (1989) Prognosis of ovarian carcinomas: Prediction by histoquantitative methods. Histopathology 15:167–178.

    Article  PubMed  CAS  Google Scholar 

  87. Schipper NW, Smeulders AWM, Baak JPA (1989) Evaluation of automated estimation of epithelial volume and its prognostic value in ovarian tumors. Lab Invest 61:228–234.

    PubMed  CAS  Google Scholar 

  88. Haapasalo H, Collan Y, Seppa A, et al. (1990) Prognostic value of ovarian carcinoma grading methods: A method comparison study. Histopathology 16:1–7.

    Article  PubMed  CAS  Google Scholar 

  89. Diest PJ van, Baak JPA, Brugghe J, et al. (1994) Quantitative prognostic features as predictors of long-term survival in patients with advanced ovarian cancer treated with cisplatin. Int J Gynecol Cancer 3:174–180.

    Article  Google Scholar 

  90. Ludescher C, Weger AR, Lindholm J, et al. (1990) Prognostic significance of tumor cell morphometry, histopathology, and clinical parameters in advanced ovarian carcinoma. Int J Gynecol Pathol 9:343–351.

    Article  PubMed  CAS  Google Scholar 

  91. Hogberg T, Wang G, Risberg B, et al. (1992) Nuclear morphometry: A strong prognostic factor for survival after secondary surgery in advanced ovarian cancer. Int J Gynecol Cancer 2:198–206.

    Article  PubMed  Google Scholar 

  92. Brinkhuis M, Baak JPA, Diest PA van, Lund B, Wils J (1996) In Dutch and Danish patients with FIGO III ovarian carcinoma, geographic survival differences are associated with differences in quantitative pathologic features. Int J Gynecol Cancer 6:108–114.

    Article  Google Scholar 

  93. Brinkhuis M, Lund B, Meijer GA, Bak JPA (1996) Quantitative pathologic variables as prognostic factors for overall survial in Danish patients with FIGO stage III ovarian cancer. Int J Gynecol Cancer 6:168–174.

    Article  Google Scholar 

  94. Budwit-Novotny DA, McCarty KS, Cox EB, et al. (1986) Immunohistochemical analysis of estrogen receptor in endometrial adenocarcinoma using a monoclonal antibody. Cancer Res 46:5419–5425.

    PubMed  CAS  Google Scholar 

  95. Carcangiu ML, Chambers JT, Voynick IM, Pirro M, Schwartz PE (1990) Immunohistochemical evaluation of estrogen and progesterone receptor content in 183 patients with endometrial carcinoma. Am J Clin Pathol 94:247–254.

    PubMed  CAS  Google Scholar 

  96. Chambers JT, Carcangiu ML, Voynick IM, Schwartz PE (1990) Immunohistochemical evaluation of estrogen and progesterone receptor content in 183 patients with endometrial carcinoma. II. Correlation between biochemical and immunohistological methods and survival. Am J Clin Pathol 34:255–260.

    Google Scholar 

  97. Snijders MP, de-Goeij AF, Koudstaal J, et al. (1990) Is immunohistochemical analysis of oestrogen and progesterone receptors in endometrial carcinoma superior to the radioligand binding assay?. J Pathol 161:129–135.

    Article  PubMed  CAS  Google Scholar 

  98. Aasmundstad TA, Haugen OA, Johannesen E, Hoe AL, Kvinsland S (1992) Oestrogen receptor analysis: Correlation between enzyme immunoassay and immunohistochemical methods. J Clin Pathol 43:125–129.

    Article  Google Scholar 

  99. Nyholm HCJ, Nielsen AL, Lyndrup J, Drreisler A, Thorpe SM (1993) Estrogen and progesterone receptors in endometrial carcinoma: Comparison of immunohistochemical and biochemical analysis. Int J Gynecol Pathol 12:246–252.

    Article  PubMed  CAS  Google Scholar 

  100. Chambers JT (1988) Sex steroid receptors in endometrial cancer. Yale J Biol Med 61:339–350.

    PubMed  CAS  Google Scholar 

  101. Huang SJ, Cheng L, Lewin KJ, Fu YS (1991) Immunohistochemical estrogen receptor assessment in hyperplastic, neoplastic, and physiologic endometria. Pathol Res Pract 187:487–495.

    Article  PubMed  CAS  Google Scholar 

  102. Creasman W, Soper JT, McCarty JS Jr., et al. (1985) Influence of cytoplasmic steroid receptor content on prognosis of early stage endometrial carcinoma. Am J Obstet Gynecol 131:922–932.

    Google Scholar 

  103. Ehrlich CE, Young PC, Stehman FB, Sutton GP, Alford WM (1988) Steroid receptors and clinical outcome in patients with adenocarcinoma of the endometrium. Am J Obstet Gynecol 158:796–807.

    PubMed  CAS  Google Scholar 

  104. Ingram SS, Rosenman J, Heath R, Morgan TM, Moore D, Varia M (1989) The predictive value of progesterone receptor levels in endometrial cancer. Int J Radiat Oncol Biol Phys 17:21–27.

    Article  PubMed  CAS  Google Scholar 

  105. Borazjani G, Twiggs LB, Leung BS, Prem KA, Adcock LL, Cardon LF (1989) Prognostic significance of steroid receptors measured in primary, metastatic and recurrent endometrial carcinoma. Am J Obstet Gynecol 161:1253–1257.

    PubMed  CAS  Google Scholar 

  106. Segreti EM, Novotny DB, Soper JT, Mutch DG, Creasman WT, McCarty KS (1989) Endometrial cancer: Histologic correlates of immunohistochemical localization of progesterone receptor and estrogen receptor. Obstet Gynecol 73:780–785. Tornos C, Silva EG, el Naggar A, Burke TW (1992) Aggressive stage I grade I endometrial carcinoma. Cancer 70:790-798.

    PubMed  CAS  Google Scholar 

  107. Creasman WT (1993) Prognostic significance of hormone receptors in endometrial cancer. Cancer 71:287–288.

    Article  Google Scholar 

  108. Kerner H, Sabo E, Friedman M, Beck D, Samare O, Lichtig C (1995) An immunohistochemical study of estrogen and progesterone receptors in adenocarcinoma of the endometrium and in the adjacent mucosa. Int J Gynecol Cancer 8:275–281.

    Article  Google Scholar 

  109. Bizzi A, Codegoni AM, Landoni F, et al. (1988) Steroid receptors in epithelial ovarian carcinoma: Relation to clinical parameters and survival. Cancer Res 48:6222–6226.

    PubMed  CAS  Google Scholar 

  110. Rose PJ, Reale FR, Longcope C, Hunter RE (1990) Prognostic significance of estrogen and progesterone receptors in ovarian epithelial cancer. Obstet Gynecol 76:258–263.

    PubMed  CAS  Google Scholar 

  111. Sevelda P, Denison U, Schemper M, et al. (1990) Oestrogen and progesterone receptor content as a prognostic factor in advanced epithelial ovarian carcinoma. Br J Obstet Gynaecol 97:706–712.

    Article  PubMed  CAS  Google Scholar 

  112. Slotman BJ, Narta JJP, Rao BR (1990) Survival of patients with ovarian cancer: Apart from stage and grade, tumor progesterone receptor content is a prognostic indicator. Cancer 66:740–744.

    Article  PubMed  CAS  Google Scholar 

  113. Leake RE, Owens O (1990) The prognostic value of steroid receptors, growth factors and growth factor receptors in ovarian cancer. In: Sharp F, Mason WP, Leake RE, eds. Ovarian Cancer: Biological and Therapeutic Challenges. London: Chapman and Hall, pp. 69–75.

    Google Scholar 

  114. Hunter RE, Longcope C, Keough P (1987) Steroid hormone receptors in carcinoma of the cervix. Cancer 60:392–396.

    Article  PubMed  CAS  Google Scholar 

  115. Harding M, Mcintosh J, Paul M, et al. (1990) Oestrogen and progesterone receptors in carcinoma of the cervix. Clin Oncol 2:313–317.

    Article  CAS  Google Scholar 

  116. Darne J, Soutter WP, Ginsberg R, Sharpe F (1990) Nuclear and ‘cytoplasmic’ estrogen and progesterone receptors in squamous cell carcinoma of the cervix. Gynecol Oncol 38:216–219.

    Article  PubMed  CAS  Google Scholar 

  117. Scott RJ, Hall PA, Haldane JS, et al. (1991) A comparison of immunohistochemical markers of cell proliferation with experimentally determined growth fraction. J Pathol 165:173–178.

    Article  PubMed  CAS  Google Scholar 

  118. Hall PA, Levison DA (1990) Assessment of cellular proliferation in histological material. J Clin Pathol 43:184–192.

    Article  PubMed  CAS  Google Scholar 

  119. McCormick D, Chong H, Hobbs C, Datta C, Hall PA (1993) Detection of the Ki67 antigen in fixed and wax embedded sections with the monoclonal antibody MIB1. Histopathology 22:355–360.

    Article  PubMed  CAS  Google Scholar 

  120. Konishi I, Jujii S, Nonogaki H, Nanbu Y, Iwai T, Mori T (1991) Immunohistochemical analysis of estrogen receptors, progesterone receptors, Ki-67 antigen, and human papillomavirus DNA in normal and neoplastic epithelium of the uterine cervix. Cancer 68:1340–1350.

    Article  PubMed  CAS  Google Scholar 

  121. Shurbaji MS, Brooks SK, Thurmond TS (1993) Proliferating cell nuclear antigen: Immunore-activity in cervical intraepithelial neoplasia and benign cervical epithelium. Am J Clin Pathol 100:22–26.

    PubMed  CAS  Google Scholar 

  122. Mittal KR, Demopoulos RJ, Goswami S (1993) Proliferating cell nuclear antigen (cyclin) expression in normal and abnormal squamous epithelia. Am J Surg Pathol 17:117–122.

    Article  PubMed  CAS  Google Scholar 

  123. Raju GC (1994) Expression of the proliferating cell nuclear antigen in cervical neoplasia. Int J Gynecol Pathol 13:337–341.

    Article  PubMed  CAS  Google Scholar 

  124. McLuggage WG, Buhidma M, Tang L, Maxwell P, Bharucha H (1996) Monoclonal antibody MIB1 in the assessment of cervical squamous intraepithelial lesions. Int J Gynecol Pathol 15:131–136.

    Article  Google Scholar 

  125. Hoeven KH van, Kovatich AJ (1996) Immunohistochemical staining for proliferating cell nuclear antigen, BCL2, and Ki-67 in vulvar tissues. Int J Gynecol Pathol 15:10–16.

    Article  PubMed  Google Scholar 

  126. Oka K, Hoshi T, Arai T (1992) Prognostic significance of the PC10 index as a prospective assay for cervical cancer treated with radiation therapy alone. Cancer 70:1545–1550.

    Article  PubMed  CAS  Google Scholar 

  127. Al-Nafussi AI, Klys HS, Rebello G, Kelly C, Kerr G, Cowie V (1993) The assessment of proliferating cell nuclear antigen (PCNA) immunostaining in the uterine cervix and cervical squamous neoplasia. Int J Gynecol Cancer 3:154–158.

    Article  PubMed  Google Scholar 

  128. Cole DJ, Brown DC, Crossley F, Alcock CJ, Gatter KC (1992) Carcinoma of the cervix uteri: An assessment of the relationship of tumour proliferation to prognosis. Br J Cancer 65:783–785.

    Article  PubMed  CAS  Google Scholar 

  129. Oka K, Arai T (1996) MIB1 growth fraction is not related to prognosis in cervical squamous cell carcinoma treated with radiotherapy. Int J Gynecol Pathol 15:23–27.

    Article  PubMed  CAS  Google Scholar 

  130. Garzetti GG, Ciavattini A, Goteri G, et al. (1996) Proliferating cell nuclear antigen (PCNA) immunoreactivity in stage I endometrial cancer: A new prognostic factor. Int J Gynecol Cancer 6:186–192.

    Article  Google Scholar 

  131. Nielsen AL, Nyholm HCJ, Engel P (1994) Expression in MIB-1 (paraffin ki-67) and AgNOR morphology in endometrial adenocarcinomas of endometrioid type. Int J Gynecol Pathol 13:37–44.

    Article  PubMed  CAS  Google Scholar 

  132. Hendricks JB, Wilkinson EJ, Kubiiis P, Drew P, Blaydes SM, Munakata S (1994) Ki-67 expression in vulvar carcinoma. Int J Gynecol Pathol 13:205–210.

    Article  PubMed  CAS  Google Scholar 

  133. Guo L-N, Wilkinson N, Buckley CH, Fox H, Hale RJ, Chawner L (1993) Proliferating cell nuclear antigen (PCNA) immunoreactivity in ovarian serous and mucinous neoplasms: Diagnostic and prognostic value. Int J Gynecol Cancer 3:391–394.

    Article  PubMed  Google Scholar 

  134. Isola J, Kallioniemi O-P, Korte J-M, et al. (1990) Steroid receptors and Ki-67 reactivity in ovarian cancer and in normal ovary: Correlation with DNA flow cytometry, biochemical receptor assay, and patient survival. J Pathol 162:295–301.

    Article  PubMed  CAS  Google Scholar 

  135. Kerns BM, Jordan PA, Faerman LL, Berchuck A, Bast RC (1994) Determination of proliferation index with MIB-1 in advanced ovarian cancer using quantitative image analysis. Am J Clin Pathol 101:192–197.

    PubMed  CAS  Google Scholar 

  136. Hendriksen R (1994) Ovarian Carcinogenesis: A Study of Markers for Growth Regulatory Mechanisms in Epithelial Ovarian Tumors. Dissertation, University of Uppsala, Uppsala, Sweden.

    Google Scholar 

  137. de Nictolis M, Garbisa S, Lucarini G, et al. (1996) 72 kilodalton type IV collagenase, type IV collagen, and Ki67 in serous tumors of the ovary: A clinicopathologic, immunohistochemical, and serological study. Int J Gynecol Pathol 15:102–109.

    Article  PubMed  Google Scholar 

  138. Inoue M, Fujita M, Enomoto T, et al. (1994) Immunohistochemical analysis of p53 in gynecologic tumors. Am J Clin Pathol 102:665–670.

    PubMed  CAS  Google Scholar 

  139. Levine AJ, Momand J, Finley CA (1991) The p53 tumour suppressor gene. Nature 351:453–456.

    Article  PubMed  CAS  Google Scholar 

  140. Dowell SP, Hall PA (1994) The clinical relevance of the p53 tumour suppression gene. Cytopathology 5:133–145.

    Article  PubMed  CAS  Google Scholar 

  141. Wynford-Thomas D (1992) p53 in tumour pathology: Can we trust immunocytochemistry?. J Pathol 166:329–330.

    Article  PubMed  CAS  Google Scholar 

  142. Marks JR, Davidoff AM, Kerns BJ, et al. (1991) Overexpression and mutation of p53 in epithelial ovarian cancer. Cancer Res 51:2979–2984.

    PubMed  CAS  Google Scholar 

  143. Eccles DM, Brett L, Lessells A, et al. (1992) Overexpression of the p53 protein and allelic loss of 17p13 in ovarian carcinoma. Br J Cancer 65:40–44.

    Article  PubMed  CAS  Google Scholar 

  144. Kupryjanczyk J, Thor AD, Beauchamp R, et al. (1993) p53 gene mutations and protein accumulation in human ovarian cancer. Proc Natl Acad Sci USA 90:4961–4965.

    Article  PubMed  CAS  Google Scholar 

  145. Kohler MF, Marks JR, Wiseman RW, et al. (1993) Spectrum of mutation and frequency of allelic deletion of the p53 gene in ovarian cancer. J Natl Cancer Inst 85:1513–1519.

    Article  PubMed  CAS  Google Scholar 

  146. Milner BJ, Allan LA, Eccles DM, et al. (1993) p53 mutation is a common genetic event in ovarian carcinoma. Cancer Res 53:2128–2132.

    PubMed  CAS  Google Scholar 

  147. Kiyokawa T (1994) Alteration of p53 in ovarian cancer: Its occurrence and maintenance in tumor progression. Int J Gynecol Pathol 13:311–318.

    Article  PubMed  CAS  Google Scholar 

  148. Henriksen R, Strang P, Wilander E, Backstrom T, Tribukait B, Oberg K (1994) p53 expression in epithelial ovarian neoplasms: Relationship to clinical and pathological parameters, Ki-67 expression and flow cytometry. Gynecol Oncol 53:301–306.

    Article  PubMed  CAS  Google Scholar 

  149. Niwa K, Itoh M, Murase T, et al. (1994) Alteration of p53 gene in ovarian carcinoma: Clinicopathological correlation and prognostic significance. Br J Cancer 70:1191–1197.

    Article  PubMed  CAS  Google Scholar 

  150. McManus DT, Yep EPH, Maxwell P, Russell SEH, Toner PG, McGee JO’D (1994) p53 expression, mutation and allelic deletion in ovarian cancer. J Pathol 174:159–168.

    Article  PubMed  CAS  Google Scholar 

  151. Hutson R, Ramsdale J, Wells M (1995) p53 protein expression in putative precursor lesions of epithelial ovarian cancer. Histopathology 27:367–371.

    Article  PubMed  CAS  Google Scholar 

  152. Kupryjanczyk J, Bell DA, Yandell DW, Scully RE, Thor AD (1994) p53 expression in ovarian borderline tumors and Stage 1 carcinomas. Am J Clin Pathol 102:671–676.

    PubMed  CAS  Google Scholar 

  153. Levesque MA, Katsaros D, Yu H, et al. (1995) Mutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma. Cancer 75:1327–1338.

    Article  PubMed  CAS  Google Scholar 

  154. Klemi PJ, Takahashi S, Joensuu H, Kiiholma P, Narimatsu E, Mori M (1994) Immunohistochemical detection of p53 protein in borderline and malignant serous ovarian tumors. Int J Gynecol Pathol 13:228–233.

    Article  PubMed  CAS  Google Scholar 

  155. Hartmann LC, Podratz KC, Keeney GL, et al. (1994) Prognostic significance of p53 immunostaining in epithelial ovarian cancer. J Clin Oncol 12:64–69.

    PubMed  CAS  Google Scholar 

  156. Allan LA, Campbell MK, Eccles RCF, et al. (1996) The significance of p53 mutation and over-expression in ovarian cancer prognosis. Int J Gynecol Cancer 6, in press.

    Google Scholar 

  157. Wertheim I, Muto MG, Welch WR, Bell DA, Berkowitz RS, Mok SC (1994) p53 gene mutation in human borderline epithelial ovarian tumors. J Natl Cancer Inst 86:1549–1551.

    Article  PubMed  CAS  Google Scholar 

  158. Berchuck A, Kohler M, Hopkins MP, et al. (1994) Overexpression of p53 is not a feature of benign and earlystage borderline epithelial ovarian tumors. Gynecol Oncol 52:232–236.

    Article  PubMed  CAS  Google Scholar 

  159. Marcelli AR, Demopoulos RI, Goswami S, Mittal KR (1996) Comparison of p53 and MIB1 expression in benign and borderline areas of ovarian serous tumors. Int J Gynecol Pathol 15:39–44.

    Article  PubMed  CAS  Google Scholar 

  160. Khalifa MA, Mannel RS, Haraway SD, et al. (1994) Expression of EGFR, HER/2-neu, p53 and PCNA in endometrioid, serous papillary, and clear cell endometrial adenocarcinomas. Gynecol Oncol 53:84–92.

    Article  PubMed  CAS  Google Scholar 

  161. Inoue M, Okayama A, Fujita M, et al. (1994) Clinicopathological characteristics of p53 over-expression in endometrial cancers. Int J Cancer 58:14–19.

    Article  PubMed  CAS  Google Scholar 

  162. Prat J, Oliva E, Lerma E, Vaquero M, Matiasguiu X (1994) Uterine papillary serous adenocarcinoma: A 10-case study of p53 and c-erb-B2 expression and DNA content. Cancer 74:1773–1783.

    Article  Google Scholar 

  163. Kohler MF, Berchuck A, Davidoff AM, et al. (1992) Overexpression and mutation of p53 in endometrial carcinoma. Cancer Res 52:1622–1627.

    PubMed  CAS  Google Scholar 

  164. Yu CC-W, Wilkinson N, Brito MJ, et al. (1993) Patterns of immunohistochemical staining for proliferating nuclear antigen and p53 in benign and neoplastic human endometrium. Histopathology 23:367–371.

    Article  PubMed  CAS  Google Scholar 

  165. Ito K, Watanabe K, Nasim S, et al. (1994) Prognostic significance of p53 overexpression in endometrial cancer. Cancer Res 54:4667–4670.

    PubMed  CAS  Google Scholar 

  166. Tsuda H, Hirohasi S (1992) Frequent occurrence of p53 gene mutations in uterine cancers at advanced clinical stage and with aggressive histological phenotypes. Jpn J Cancer Res 83:1184–1191.

    Article  PubMed  CAS  Google Scholar 

  167. Hachisuga T, Fukuda K, Uchiyama M, Matsuo N, Iwasaka T, Sugimori H (1993) Immunohistochemical study of p53 expression in endometrial carcinomas: Correlation with markers of proliferating cells and clinicopathologic features. Int J Gynecol Cancer 3:363–368.

    Article  PubMed  Google Scholar 

  168. Reinartz JJ, George E, Lindgren BR, Niehans GA (1994) Expression of p53, transforming growth factor alpha, epidermal growth factor receptor and c-erbB-2 in endometrial carcinoma and correlation with survival and known predictors of survival. Hum Pathol 25:1075–1083.

    Article  PubMed  CAS  Google Scholar 

  169. Nielson AL, Nyholm HCJ (1994) p53 protein and c-erbB-2 protein (p185) in endometrial adenocarcinoma of endometrioid type: An immunohistochemical examination on paraffin sections. Am J Clin Pathol 102:76–79.

    Google Scholar 

  170. Scheffner M, Werness BA, Huibregate JM, Levine AJ, Howley PM (1990) The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63:1129–1136.

    Article  PubMed  CAS  Google Scholar 

  171. Crook T, Wrede D, Tidy JA, Mason WP, Evans DJ, Vousden KH (1992) Clonal p53 mutation in primary cervical cancer: Association with human-papillomavirus-negative tumours. Lancet 330:1070–1073.

    Article  Google Scholar 

  172. Tidy JA, Wrede D (1992) Tumor suppression genes: New pathways in gynecological cancer. Int J Gynecol Cancer 2:1–8.

    Article  PubMed  Google Scholar 

  173. Riou G, Favre M, Jeannel D, Bourhis J, Le Doussal V, Orth G (1990) Association between poor prognosis in early-stage invasive cervical carcinomas and non detection of HPV DNA. Lancet 335:1171–1174.

    Article  PubMed  CAS  Google Scholar 

  174. Higgins GD, Davy M, Roder D, Uzelin DM, Phillips GE, Burrell CJ (1991) Increased age and mortality associated with cervical carcinoma negative for human papillomavirus RNA. Lancet 338:910–913.

    Article  PubMed  CAS  Google Scholar 

  175. Fujita M, Inoue M, Tanizawa O, Iwamoto S, Enomoto T (1992) Alterations of the p53 gene in human primary cervical carcinoma with and without human papillomavirus infection. Cancer Res 52:5323–5328.

    PubMed  CAS  Google Scholar 

  176. Srivastava S, Tong YA, Devadas K, et al. (1992) The status of the p53 gene in human papilloma virus positive or negative cervical carcinoma cell lines. Carcinogenesis 12:1273–1275.

    Article  Google Scholar 

  177. Isuda S, Hirohashi S (1992) Frequent occurrence of p53 gene mutations in uterine cancers at advanced clinical stage and with aggressive histological phenotypes. Jpn Cancer Res 83:1184–1191.

    Article  Google Scholar 

  178. Choo KB, Chong KY (1993) Absence of mutation in the p53 and retinoblastoma susceptibility genes in primary cervical carcinomas. Virology 193:1042–1046.

    Article  PubMed  CAS  Google Scholar 

  179. Isawaka T, Oh-Uchida M, Matsuo N, et al. (1993) Correlation between HPV positivity and state of the p53 gene in cervical carcinoma cell lines. Gynecol Oncol 48:104–109.

    Article  Google Scholar 

  180. Busby-Earle RMC, Steel CM, Williams ARW, Cohen B, Bird CC (1994) p53 mutations in cervical carcinogenesis: Low frequency and lack of correlation with human papilloma status. Br J Cancer 69:732–737.

    Article  PubMed  CAS  Google Scholar 

  181. Lee JH, Kang YS, Koh JW, et al. (1994) p53 gene mutation is rare in human cervical carcinomas with positive HPV sequences. Int J Gynecol Cancer 4:371–378.

    Article  PubMed  Google Scholar 

  182. Jeffers MD, Richmond J, Farquharson M, Menicol M (1994) p53 immunoreactivity in cervical intraepithelial neoplasia and non-neoplastic cervical squamous epithelium. J Clin Pathol 47:1073–1076.

    Article  PubMed  CAS  Google Scholar 

  183. Miwa K, Miyamoto S, Kato H, et al. (1995) The role of p53 inactivation in human cervical cell carcinoma development. Br J Cancer 71:219–226.

    Article  PubMed  CAS  Google Scholar 

  184. Harmselter B, Belkum A van, Quint W, et al. (1995) p53 and human papilloma virus type 16 in cervical intraepithelial neoplasia and carcinoma. Int J Gynecol Pathol 14:125–133.

    Article  Google Scholar 

  185. Hellstrom AC, Hue J, Silfversward C, Auer G (1994) DNA-ploidy and mutant p53 overexpression in primary fallopian tube cancer. Int J Gynecol Cancer 4:408–413.

    Article  PubMed  Google Scholar 

  186. Watson JV, Curling OM, Hudson CN (1990) Flow cytometric quantitation of p62myc and DNA in serous papillary ovarian cancer. In: Sharp F, Mason WP, Leake RE, eds. Ovarian Cancer: Biological and Therapeutic Challenges. London: Chapman & Hall, pp. 123–138.

    Google Scholar 

  187. Sasano H, Nagura H, Silverberg SG (1992) Immunolocalization of c-myc oncoprotein in mucinous and serous adenocarcinomas of the ovary. Hum Pathol 23:491–495.

    Article  PubMed  CAS  Google Scholar 

  188. Polocarz SV, Hey NA, Stephenson TJ, Hill AS (1990) C-myc oncogene product P62c-myc in ovarian mucinous neoplasms: immunohistochemical study correlated with malignancy. J Clin Pathol 42:896–899.

    Google Scholar 

  189. Bauknecht T, Bermelin G, Kommoss F (1990) Clinical significance of oncogenes and growth factors in ovarian carcinoma. J Steroid Biochem Med Biol 37:855–862.

    Article  CAS  Google Scholar 

  190. van Dam PA, Vergote IB, Lowe DG, et al. (1994) Expression of c-erbB-2, c-myc, and c-ras oncoproteins, insulin-like growth factor receptor 1, and epidermal growth factor receptor in ovarian carcinoma. J Clin Pathol 47:914–919.

    Article  PubMed  Google Scholar 

  191. Park JS, Kim HK, Han SK, Lee JM, Namkoong SE, Kim SJ (1995) Detection of c-K-ras point mutation in ovarian cancer. Int J Gynecol Cancer 5:107–111.

    Article  PubMed  Google Scholar 

  192. Yaginuma Y, Yamashita K, Kuzumaki N, et al. (1992) ras oncogene product p21 expression and prognosis of human ovarian tumors. Gynecol Oncol 46:45–50.

    Article  PubMed  CAS  Google Scholar 

  193. Scambia G, Catozzi L, Panici PB, et al. (1993) Expression of ras p21 protein in normal and neoplastic ovarian tissues: Correlation with histopathologic features and receptors for estrogen, progesterone, and epidermal growth factor. Am J Obstet Gynecol 168:71–78.

    PubMed  CAS  Google Scholar 

  194. Leeson SC, Morphopoulos G, Buckley CH, Hale RJ (1995) c-erbB2 oncogene expression in stage 1 epithelial ovarian cancer. Br J Obstet Gynaecol 102:65–67.

    Article  PubMed  CAS  Google Scholar 

  195. Felip E, Del Campo JM, Rubio D, Vidal MT, Colomer R, Bermejo B (1995) Overexpression of c-erbB-2 in epithelial ovarian cancer. Cancer 75:2147–2152.

    Article  PubMed  CAS  Google Scholar 

  196. Berchuck A, Kamel A, Whitaker R, et al. (1990) Overexpression of HER-2/neu is asociated with poor survival in advanced epithelial ovarian cancer. Cancer Res 50:4087–4091.

    PubMed  CAS  Google Scholar 

  197. Meden H, Marx D, Rath W, et al. (1994) Overexpression of the oncogene c-erbB-2 in primary ovarian cancer: Evaluation of the prognostic value in a Cox proportional hazards multiple regression. Int J Gynecol Pathol 13:45–53.

    Article  PubMed  CAS  Google Scholar 

  198. Haldane JS, Hird V, Hughes CM, Gullick WJ (1990) c-erbB-2 oncogene expression in ovarian cancer. J Pathol 162:231–237.

    Article  PubMed  CAS  Google Scholar 

  199. Wilkinson N, Todd N, Buckley CH, Gusterson BA, Fox H (1991) An immunohistochemical study of the incidence and significance of C-erbB-2 oncoprotein overexpression in ovarian neoplasia. Int J Gynecol Cancer 1:285–289.

    Article  Google Scholar 

  200. Rubin SC, Finstad CL, Wong GY, et al. (1993) Prognostic significance of HER-2/neu expression in advanced epithelial ovarian cancer: A multivariate analysis. Am J Obstet Gynecol 168:162–169.

    PubMed  CAS  Google Scholar 

  201. Rubin SC, Finstad CL, Federici MG, et al. (1994) Prevalence and significance of HER-2/neu expression in early epithelial ovarian cancer. Cancer 73:1456–1459.

    Article  PubMed  CAS  Google Scholar 

  202. Singleton TP, Perrone T, Oakley G, et al. (1994) Activation of c-erbB-2 and prognosis in ovarian carcinoma. Cancer 73:1460–1466.

    Article  PubMed  CAS  Google Scholar 

  203. Makar AP, Holm R, Kristensen GB, Nesland JM, Trope CG (1994) The expression of c-erbB-2 (HER-2/neu) oncogene in invasive ovarian malignancies. Int J Gynecol Cancer 4:194–199.

    Article  PubMed  Google Scholar 

  204. Monk BJ, Chapman JA, Johnson GA, et al. (1994) Correlation of c-myc and HER-2/neu amplificaton and expression with histopathologic variables in uterine corpus cancer. Am J Obstet Gynecol 171:1193–1198.

    PubMed  CAS  Google Scholar 

  205. Sato S, Ito K, Ozawa N, et al. (1991) Expression of c-myc, epidermal growth factor receptor and c-erbB-2 in human endometrial carcinoma and cervical adenocarcinoma. Tohoku J Exp Med 165:137–145.

    Article  PubMed  CAS  Google Scholar 

  206. Bai MK, Costopoulos JS, Christofiridou BP, Papadimitrou CS (1994) Immunochemical detection of the c-myc oncogene product in normal, hyperplastic and carcinomatous endometrium. Oncology 51:314–319.

    Article  PubMed  CAS  Google Scholar 

  207. Boyd J, Risinger JL (1991) Analysis of oncogene alterations in human endometrial carcinoma: Prevalence of ras mutations. Mol Carcinogen 4:189–195.

    Article  CAS  Google Scholar 

  208. Enomoto T, Inoue M, Perantoni AO, et al. (1991) K-ras activation in premalignant and malignant epithelial lesions of the human uterus. Cancer Res 51:5308–5314.

    PubMed  CAS  Google Scholar 

  209. Enomoto T, Fujita M, Inoue M, et al. (1993) Alterations of the p53 tumor suppressor gene and its association with activation of the c-k-ras-2 protooncogene in premalignant and malignant lesions of the human uterine endometrium. Cancer Res 53:1883–1888.

    PubMed  CAS  Google Scholar 

  210. Caduff RF, Johnston CM, Frank TS (1995) Mutations of the Ki-ras oncogene in carcinoma of the endometrium. Am J Pathol 146:182–188.

    PubMed  CAS  Google Scholar 

  211. Tsuda H, Jiko K, Yajima M, et al. (1995) Frequent occurrence of ci-K-ras gene mutations in well differentiated endometrial adenocarcinoma showing infiltrative local growth with fibrosing stromal response. Int J Gynecol Pathol 14:255–259.

    Article  PubMed  CAS  Google Scholar 

  212. Scambia G, Catozzi L, Benedetti-Panici P, et al. (1993) Expression of ras p21 oncoprotein in normal and neoplastic human endometrium. Gynecol Oncol 50:339–346.

    Article  PubMed  CAS  Google Scholar 

  213. Milde-Langosch K, Wichens V, Brack T, Loning T (1991) Nachweis und biologische Bedeutung von Viren und Onkogenen bei Uteruskarzinomen. Verh Dtsch Ges Pathol 75:363–365.

    PubMed  CAS  Google Scholar 

  214. Hetzel DJ, Wilson TO, Keeney GL, et al. (1992) HER-2/neu expression: A major prognostic factor in endometrial cancer. Gynecol Oncol 47:179–185.

    Article  PubMed  CAS  Google Scholar 

  215. Wang D, Konishi I, Koshiyama M, et al. (1993) Expression of c-erbB-2 protein and epidermal growth factor receptor in endometrial carcinomas: Correlation with clinicopathologic and sex steroid receptor status. Cancer 72:2628–2637.

    Article  PubMed  CAS  Google Scholar 

  216. Khalifa MA, Mannel RS, Haraway SD, Walker J, Min KW (1994) Expression of EGFR, HER-2/neu, p53, and PCNA in endometrioid, serous papillary, and clear cell endometrial adenocarcinomas. Gynecol Oncol 53:84–92.

    Article  PubMed  CAS  Google Scholar 

  217. Czerwenka K, Lu Y, Heuss F (1995) Amplification and expression of the c-erbB-2 oncogene in normal, hyperplastic and malignant endometria. Int J Gynecol Pathol 14:98–106.

    Article  PubMed  CAS  Google Scholar 

  218. Prat J, Oliva E, Lerma E, Vaquero M, Matias Guiu X (1994) Uterine papillary serous adenocarcinoma: A 10-case study of p53 and c-erbB-2 expression and DNA content. Cancer 74:1778–1783.

    Article  PubMed  CAS  Google Scholar 

  219. Pisani AL, Barbuto DA, Chen D, Ramos L, Lagasse LD, Karlan BY (1995) HER-2/neu, p53 and DNA analyses as prognosticators for survival in endometrial carcinoma. Obstet Gynecol 85:729–734.

    Article  PubMed  CAS  Google Scholar 

  220. Reinartz JJ, George E, Lindgren BR, Niehans GA (1994) Expression of p53, transforming growth alpha, epidermal growth factor receptor and c-erbB-2 in endometrial carcinoma and correlation with survival and known predictors of survival. Hum Pathol 25:1075–1083.

    Article  PubMed  CAS  Google Scholar 

  221. Santini D, Ceccarelli C, Martineiii GN, et al. (1994) Immunocytochemical study of epidermal growth factor receptor, transforming growth factor alpha, and’ squamous differentiation’ in human endometrial carcinoma. Hum Pathol 25:1319–1323.

    Article  PubMed  CAS  Google Scholar 

  222. Ocadiz R, Sauceda R, Cruz M, Graef AM, Gariglio P (1987) High correlation between molecular alterations of the c-myc oncogene and carcinoma of the uterine cervix. Cancer Res 47:4173–4177.

    PubMed  CAS  Google Scholar 

  223. Kohler M, Janz I, Wintzer HO, Wagner E, Bauknecht T (1989) The expression of EGF receptors, EFF-like factors and c-myc in ovarian and cervical carcinomas and their potential clinical significance. Anticancer Res 9:1537–1547.

    PubMed  CAS  Google Scholar 

  224. Riou G, Barrois M, Le MG, George M, Doussal VL, Haie C (1987) C-myc proto-oncogene expression and prognosis in early carcinoma of the uterine cervix. Lancet 1:761–763.

    Article  PubMed  CAS  Google Scholar 

  225. Sowani A, Ong G, Dische S, et al. (1989) C-myc oncogene expression and clinical outcomes in carcinoma of the cervix. Mol Cell Probes 3:117–123.

    Article  PubMed  CAS  Google Scholar 

  226. Bourhis J, Le MG, Barrois M, et al. (1990) Prognostic value of c-myc-proto-oncogene overexpression in early invasive carcinoma of the cervix. J Clin Oncol 8:1789–1796.

    PubMed  CAS  Google Scholar 

  227. Riou G, Bourhis J, Le GM (1990) The c-myc proto-oncogene in invasive carcinomas of the uterine cervix: Clinical relevance of overexpression in early stages of the cancer. Anticancer Res 10:1225–1231.

    PubMed  CAS  Google Scholar 

  228. Iwasaka T, Yokoyama M, Oh-Uchida M, et al. (1992) Detection of human papillomavirus genome and analysis of c-myc and Ha-ras oncogenes in invasive cervical carcinomas. Gynecol Oncol 46:298–303.

    Article  PubMed  CAS  Google Scholar 

  229. Symonds RP, Habeshaw T, Paul J, et al. (1992) No correlation between ras, c-myc and c-jun proto-oncogene expression and prognosis in advanced carcinoma of the cervix. Eur J Cancer 28A:1616–1617.

    Google Scholar 

  230. Falcinelli C, Luzi P, Alberti P, et al. (1993) Human papilloma virus infection and Ki-ras oncogene in paraffin-embedded squamous carcinomas of the cervix. Gynecol Obstet Invest 36:185–188.

    Article  PubMed  CAS  Google Scholar 

  231. Hayashi Y, Hachisuga T, Iwasaka T, et al. (1991) Expression of ras oncogene product and EGF receptor in cervical squamous cell carcinomas and its relationship to lymph node involvement. Gynecol Oncol 40:147–151.

    Article  PubMed  CAS  Google Scholar 

  232. Hale RJ, Buckley CH, Fox H, Williams J (1992) Prognostic value of c-erbB-2 expression in uterine cervical carcinoma. J Clin Pathol 45:594–596.

    Article  PubMed  CAS  Google Scholar 

  233. Kihana T, Tsuda H, Teshima S, et al. (1994) Prognostic significance of the overexpression of c-erbB-2 protein in adenocarcinoma of the uterine cervix. Cancer 73:148–153.

    Article  PubMed  CAS  Google Scholar 

  234. Mitra AB, Murty VV, Pratap M, et al. (1994) ERBB2 (HER2/neu) oncogene is frequently amplified in squamous cell carcinoma of the uterine cervix. Cancer Res 54:637–639.

    PubMed  CAS  Google Scholar 

  235. Oka K, Nakano T, Arai T (1994) c-erbB-2 oncoprotein expression is asociated with poor prognosis in squamous cell carcinoma of the cervix. Cancer 73:664–671.

    Article  PubMed  CAS  Google Scholar 

  236. Holm R, Abeler VM, Skomedal H, Nesland JM (1993) Overexpression of p53 protein and c-erbB-2 protein in small cell carcinoma of the cervix uteri. Zentralbl Pathol 139:153–156.

    PubMed  CAS  Google Scholar 

  237. Hale RJ, Buckley CH, Gullick WJ, et al. (1993) Prognostic value of epidermal growth factor receptor expression in cervical carcinoma. J Clin Pathol 46:149–153.

    Article  PubMed  CAS  Google Scholar 

  238. Hunt CR, Hale RJ, Armstrong C, Rajkumar T, Gullick WJ, Buckley CH (1995) C-erbB-3 proto-oncogene expression in uterine cervical carcinoma. Int J Gynecol Cancer 5:282–285.

    Article  PubMed  Google Scholar 

Download references

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 1998 Springer Science+Business Media New York

About this chapter

Cite this chapter

Fox, H. (1998). Advances in the pathology of gynecologic cancer. In: Ozols, R.F. (eds) Gynecologic Oncology. Cancer Treatment and Research, vol 95. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-5447-9_12

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-5447-9_12

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-7487-9

  • Online ISBN: 978-1-4615-5447-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics